Health

RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,…

4 months ago

Revive Therapeutics Announces Extension of Proposed Private Placement

TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a…

4 months ago

Helios Alliance Announces National Opioid Conference Featuring Former White House Drug Policy Director Dr. Rahul Gupta

September 05, 2025 16:45 ET  | Source: Helios Alliance Mobile, Alabama , Sept. 05, 2025 (GLOBE NEWSWIRE) -- Helios Alliance,…

4 months ago

Adagenes ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

September 05, 2025 09:55 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) --…

4 months ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE…

4 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…

4 months ago

Avania Strengthens Leadership Team with Appointment of Four New Executives

BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania, the leading global MedTech advisory and clinical development partner,…

4 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical…

4 months ago

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

September 03, 2025 17:17 ET  | Source: Senseonics Holdings, Inc. CGM commercial operations to transition from Ascensia Diabetes Care to…

4 months ago